Deals > All

East Germany North Germany South Germany West Germany Austria Germany Switzerland [ # 12 & 35 ]

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
1 2 3 4 5 ... 48 49 50

Deal: Collaboration or Financing	Date
Tubulis–BioMedPartners: investment, 202205 financing round Series B totalling €60m incl existing + co-investor BioMedPartners	2022-05-03
Tubulis–BPCE: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Seventure Partners	2022-05-03
Tubulis–Evotec: investment, 202205 financing round Series B totalling €60m incl new + co-investor Evotec	2022-05-03
Tubulis–Fund+: investment, 202205 financing round Series B totalling €60m incl new + co-investor Fund+	2022-05-03
Tubulis–Germany (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Coparion	2022-05-03
Tubulis–High-Tech Gründerfonds: investment, 202205 financing round Series B totalling €60m incl existing + co-investor HTGF	2022-05-03
Tubulis–Occident: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Occident	2022-05-03
Tubulis–SEVERAL: investment, 202205 financing round Series B €60m led by new investor Andera Partners	2022-05-03
Bionter–Dynamk Capital: investment, 202204 Series Seed financing $3m from Dynamk Capital	2022-04-27
Boehringer–CDR-Life: ophthalmic, 202204 collab development existent of antibody fragment-based therapeutic CDR202 for macular degeneration	2022-04-13
CDR-Life–Argot Partners: public relations, 202204 service existent media contact Argot Partners	2022-04-13
CDR-Life–Jeito Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor Jeito Capital	2022-04-13
CDR-Life–Omega Funds: investment, 202204 financing round Series A totalling $76m incl co-investor Omega Funds	2022-04-13
CDR-Life–RA Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor RA Capital Management	2022-04-13
CDR-Life–SEVERAL: investment, 202204 financing round Series A $76m co-led by Jeito Capital + RA Capital	2022-04-13
Cimeio Therapeutics–Versant Ventures: investment, 202204– Series A $50m commitment at launch from Versant Ventures	2022-04-13
Affimed–SEVERAL: investment, 202204 public offering $90m+$13.5m with 22.5m+3.375m common shares at $4/share PRICED	2022-04-12
Avi Medical–Balderton Capital: investment, 202204 financing round Serise B totalling €50m incl lead investor Balderton Capital	2022-04-06
Avi Medical–SEVERAL: investment, 202204 financing round Series B €50m led by Balderton Capital	2022-04-06
IonSense–Bruker: investment, 202204 acquisition of IonSense by Bruker	2022-04-06
Regeneron–ViGeneron: gene therapy, 202204– collab + option agreem to develop vgAAV-based therapeutics for one inherited retinal disease target	2022-04-06
Merck (DE)–Lonza: MAST platform, 202204 acquisiton €na of MAST automated bioreactor sampling system by Merk Life Science from Lonza	2022-04-05
Optimal Industrial–Bruker: investment, 202204 acquisition €na of Optimal Industrial Automation + Technologies by Bruker	2022-04-05
Labster–SEVERAL: investment, 202204 financing round Series C 2nd tranche $47m bringing total Series C to $107m	2022-04-04
Andes–Bayer: investment, 202204 existent portfolio company of Leaps by Bayer	2022-04-01
Ebenbuild–Bavaria (govt): investment, 202203 seed financing round totalling €2.5m incl co-lead investor Bayern Kapital	2022-03-31
Ebenbuild–High-Tech Gründerfonds: investment, 202203 seed financing round totalling €2.5m incl co-lead investor HTGF	2022-03-31
Ebenbuild–OTHER: investment, 202203 seed financing round totalling €2.5m incl well-known business angels as co-investors	2022-03-31
Ebenbuild–SEVERAL: investment, 202203 seed financing round €2.5m co-led by HTGF + Bayern Kapital with business angels	2022-03-31
Immunic–4SC: vidofludimus, 202103 settlement of remaining royalty obligations for IMU-838 for $17.25m with 50% in cash + 50% in Immunic common stock	2022-03-31
Asahi Kasei–VectivBio: apraglutide, 202203– excl license $30m upfront + $170m milestones + royalties for developm + marketing in Japan	2022-03-30
Neuron23–HBM: investment, 202203 financing round Series C totalling $100m incl existing + co-investor HBM Partners	2022-03-30
Neuron23–SEVERAL: investment, 202203 financing round Series C $100m led by SoftBank Vision Fund 2	2022-03-30
VectivBio–Kreos Capital: credit, 202203– loan facility up to $75m with minimum draw down of $10m	2022-03-30
Sanofi–IGM Biosciences: IgM antibody agonists, 202203– collab RnD + commerc ww excl $150m upfront + >$6b milestones for cancer + inflammation	2022-03-29
Innovacell–EU (govt): credit, 202203– venture debt loan of up to €15m from EIB to Innovacell AG	2022-03-24
Irubis–EU (govt): credit, 202203– convertible loan €500k from EIC Fund as part of EIC Accelerator Pilot programme	2022-03-24
Immatics–Trophic Communications: public relations, 202203 service existent by Trophic	2022-03-23
Affini-T Therapeutics–SEVERAL: investment, 202203 financing round $175m co-led by Vida Ventures + Leaps by Bayer	2022-03-22
ITM–ICIF: investment, 202203 financing round totalling €33m incl new investor Indigenous Critical Infrastructure Fund Canada	2022-03-22
ITM–Portland Holdings: investment, 202203 financing round totalling €33m incl exisiting investor PE fund managed by Portland Investment Counsel Inc	2022-03-22
ITM–SEVERAL: investment, 202203 financing round €33m from ICIF + PE fund managed by Portland Investment Counsel Inc	2022-03-22
Nucleai MD–Debiopharm: investment, 202203 financing round Series B totalling $33m incl existing + co-investor Debiopharm	2022-03-22
Nucleai MD–SEVERAL: investment, 202203 financing round Series B $33m co-led by Section 32 + Sanofi Ventures	2022-03-22
Nagi Bioscience–Switzerland (govt): grant, 202203 SERI-funded €2.5m EIC Accelerator program grant	2022-03-21
Gilde Investment–SEVERAL: investment, 202203 first + final close of €517m Gilde Healthcare Private Equity IV fund	2022-03-16
Precirix–SEVERAL: investment, 202203 financing round Series B €80 co-led by new investors Inkef Capital + Jeito Capital + Forbion	2022-03-16
BMS–Temedica: digital companion diagnostic, 202203– collab development digital companion diagnostic for psoriasis patients	2022-03-15
InfanDx–SEVERAL: investment, 202203 financing round Series A 2nd closing €2m from new + existing investors bringing total Series A to €6m	2022-03-15
PrognomiQ–Bruker: investment, 202203 financing round totalling $46m incl lead investor Bruker Corp	2022-03-15
PrognomiQ–SEVERAL: investment, 202203 financing round $46m led by Bruker Corp	2022-03-15
Ayoxxa–btov Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor b-to-v Partners Sàrl	2022-03-14
Ayoxxa–Equivation: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Equivation-Beteiligungs-GmbH	2022-03-14
Ayoxxa–North Rhine-Westphalia (govt): investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor NRW.Bank	2022-03-14
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Rainer Christine Asset Management GmbH	2022-03-14
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Riesner Verwaltungs GmbH	2022-03-14
Ayoxxa–Prosnav Capital: investment, 202203– financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital NOT REALISED	2022-03-14
Ayoxxa–ROI Verwaltungsgesellschaft: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Oetker Family Office	2022-03-14
Ayoxxa–SEVERAL: investment, 202203– financing round providing runway for 3-5 years led by new investor Prosnav Capital NOT REALISED	2022-03-14
Ayoxxa–Wellington Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Wellington Partners	2022-03-14
FGen–Ginkgo Bioworks: investment, 202203– acquisition of FGen AG by Ginkgo Bioworks for upfront payment + milestones ANNOUNCED	2022-03-14
Ginkgo Bioworks–FGen: screening technology, 202203 collab existent for several years	2022-03-14
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Matthias Bissinger	2022-03-10
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Philipp Baaske	2022-03-10
Roche–Scenic Biotech: drugs targeting genetic modifiers, 202203 collab multi-year multi-target existent with Genentech	2022-03-10
Scenic Biotech–BioMedPartners: investment, 202203 financing round Series A totalling €28m incl new + co-lead investor BioMedPartners	2022-03-10
Scenic Biotech–SEVERAL: investment, 202203 financing round Series A €28m co-led by Eir Ventures + BioMedPartners + Vesalius Biocapital	2022-03-10
Merck (DE)–Celeris Therapeutics: AI-based drug discovery, 202202– collab research small molecule binders + bifunctional degraders	2022-03-09
NEC–Vaximm: cancer vaccines, 202203 acquisition of all neoantigen cancer vaccines assets by NEC OncoImmunity	2022-03-08
Eurazeo–SEVERAL: investment, 202203 first closing €160m of Kurma Partners Growth Opportunities Fund targeting €250m	2022-03-07
Proteona–Singleron: investment, 202203 acquisition of Proteona Pte Ltd by Singleron Biotechnologies	2022-03-07
ArrePath–Boehringer: investment, 202203 seed financing round totalling $20m incl co-lead investor BIVF	2022-03-03
ArrePath–SEVERAL: investment, 202203 seed financing round $20m co-led by BIVF + Insight Partners + Innospark Ventures	2022-03-03
Epsilogen–Novartis: investment, 202203 financing round Series B totalling £30.75m incl new + lead investor Novartis Venture Fund	2022-03-02
Epsilogen–SEVERAL: investment, 202203 financing round Series B £30.75m led by new investor Novartis Venture Fund	2022-03-02
BioEcho–Ampersand: investment, 202203 minority growth equity investment €na from Ampersand Capital Partners	2022-03-01
In Ovo–ABN AMRO: investment, 202203 financing round totalling €34m incl new investor ABN AMRO	2022-03-01
In Ovo–ECBF: investment, 202203 financing round totalling €34m incl new investor ECBF	2022-03-01
In Ovo–Evonik: investment, 202203 financing round totalling €34m incl existing investor Evonik	2022-03-01
In Ovo–SEVERAL: investment, 202203 financing round €34m with ECBF + ABN AMRO et al	2022-03-01
Aphea.Bio–ECBF: investment, 202202 existent investment of ECBF	2022-02-23
Ampersand–Recipharm: investment, 202202– acquisition of Vibalogics by Recipharma AB ANNOUNCED	2022-02-18
Centauri Therapeutics–SEVERAL: investment, 202202 financing round Series A £24m with BIVF + Evotec + Novo REPAIR Impact Fund et al	2022-02-16
Climedo Health–SEVERAL: investment, 202202 seed financing round €5m led by Nauta Capital	2022-02-16
ITM–Grand Pharma: investment, 202202 equity investment €25m from strategic partner Grand Pharmaceutical Group Ltd	2022-02-16
Memo Therapeutics–SEVERAL: investment, 202202 financing round Series B 2nd closing CHF23m bringing total round to CHF37m	2022-02-16
SpliceBio–SEVERAL: investment, 202202 financing round Series A €50m co-led by UCB Ventures + Ysios Capital	2022-02-16
XO Life–SEVERAL: investment, 202202 financing round more than €2m from SeedLink + MediVentures + Aescuvest et al	2022-02-16
c-LEcta–Kerry Group: investment, 202202 acquisition 92% for €137m with management to retain balance of shares	2022-02-15
c-LEcta–SHS Capital: investment, 202202 DIVESTMENT EXIT by SHS with sale of c-Lecta to Kerry Group	2022-02-15
IMIDomics–Evotec: investment, 202202 strategic equity investment €na by Evotec	2022-02-15
NMD Pharma–Roche: investment, 202202 financing round totalling €35m incl existing + co-investor Roche Venture Fund	2022-02-15
NMD Pharma–SEVERAL: investment, 202202 financing round €35m led by new investor Jeito Capital + incl existing investors	2022-02-15
Sequana Medical –Newton Biocapital: investment, before 202202 former pre-IPO early-exit investment of NBC I fund	2022-02-15
Green Elephant Biotech–Hessen (govt): investment, 202201 pre-seed financing round totalling mid-6-digit € incl lead investor BMH	2022-02-11
Green Elephant Biotech–OTHER: investment, 202201 pre-seed financing round totalling mid-6-digit € incl business angels as co-investors	2022-02-11
Green Elephant Biotech–SEVERAL: investment, 202201 pre-seed financing round mid-6-digit € led by BMH with business angels	2022-02-11
Celeris Therapeutics–Apex Ventures: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Apex Ventures	2022-02-10
Celeris Therapeutics–i&i Biotech Fund: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor i&i Biotech Fund	2022-02-10
Celeris Therapeutics–Longevitytech.fund: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor Longevitytech.fund	2022-02-10

1 2 3 4 5 ... 48 49 50

Picture [iito] Fighting Customers 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)